Steve Haayen, a veteran sales expert, has joined Spinal Elements, Inc. as the area vice president of sales in the Western United States. He comes on board at a time when the company is planning the introduction of several new technologies over the coming months.
Steve Haayen Joins Spinal Elements
1 min read Premium comments
As indicated in the October 25, 2016 news release, “Haayen brings over 10 years of spine sales and management experience to Spinal Elements, having previously held roles with Stryker Spine, Globus Medical, Lanx, and Biomet. In his roles with each company, Haayen has led sales growth while achieving multiple President’s & Chairman’s Club Awards, and Sales Director of the Year along with leading the Representative and Distributor of the Year from his region. Furthermore, he has a depth of experience in minimally invasive (MIS) and lateral access spine systems, an area of focus for Spinal Elements.”
“We are very fortunate to have someone with Steve’s depth of knowledge in the space of our new expanding technologies. Steve’s business acumen, procedural and industry knowledge will help us continue the strong sales growth we have seen in 2016, ” added Paul Cory, Vice President of Sales at Spinal Elements.
According to the company, “Spinal Elements is introducing several new technologies over the coming months including a novel MIS lateral access system, expandable interbody devices that aid in the restoration of proper sagittal balance by expanding and lordosing, and an MIS interspinous process fixation device. The company expects strong demand for these new procedurally driven surgical solutions in addition to the robust growth seen in its current line of products. Additional Sales management positions will be filled to help address ongoing expansion.”
Steve Haayen told OTW, “We’re going to continue to build upon the momentum that’s been established by the current Spinal Elements team and introduce new procedural solutions such as our lateral system, Katana, to work with additional industry leading surgeon and sales channel partners.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.